{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-000762","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.779887+00:00","generated_at":"2026-06-20T17:51:49.069208+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Aurinia reports preliminary Q4 net revenue $28.4M; LUPKYNIS patients up to 1,525","bullets":["Preliminary Q4 2022 net revenue ~$28.4M, full-year net revenue ~$134.0M.","Net product revenue Q4 ~$28.3M, full-year ~$103.5M; 2022 guidance achieved.","LUPKYNIS patients on therapy at Dec 31, 2022: 1,525, up from 1,354 at Sep 30, 2022.","Q4 patient start forms ~406, compared to 374 in Q3 2022.","Reiterates 2023 net product revenue guidance of $120-140M; cash & investments ~$388.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-000762","json":"https://secwatch.observer/filing/0001628280-23-000762.json","markdown":"https://secwatch.observer/filing/0001628280-23-000762.md","text":"https://secwatch.observer/filing/0001628280-23-000762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023000762/0001628280-23-000762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023000762/auph-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:51:49.069208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb86967e5aa1bd09294d77e8ff93ef3bbac805cc","claim":"Aurinia Pharmaceuticals Inc. reported fourth quarter and full-year 2022 results: revenue approximately $28.4 million and $134.0 million. Guidance reaffirmed.","evidence_excerpt":"Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023000762/0001628280-23-000762-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year 2022"},{"label":"Revenue","value":"approximately $28.4 million and $134.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}